{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:35:17Z","timestamp":1792157717934,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020098","name":"Innovative Health Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["22TACT01"],"award-info":[{"award-number":["22TACT01"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["101172722"],"award-info":[{"award-number":["101172722"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["101172788"],"award-info":[{"award-number":["101172788"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["95663957"],"award-info":[{"award-number":["95663957"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FE1573\/7-1 \/ 714209"],"award-info":[{"award-number":["FE1573\/7-1 \/ 714209"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1053\/j.semnuclmed.2025.12.003","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T11:52:57Z","timestamp":1766663577000},"page":"229-234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The value of PSMA PET for risk stratification in prostate cancer: an update and future aspects"],"prefix":"10.1053","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4745-3501","authenticated-orcid":false,"given":"Caner","family":"Civan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine J.","family":"Karpinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kambiz","family":"Rahbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1053\/j.semnuclmed.2025.12.003_bib0001","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.2967\/jnumed.120.242180","article-title":"Impact of (68)Ga-PSMA-11 PET on the management of recurrent prostate cancer in a prospective single-arm clinical trial","volume":"61","author":"Fendler","year":"2020","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.12.003_bib0002","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.233023","article-title":"PSMA PET parameters for predicting outcomes in patients with prostate cancer","volume":"309","author":"Civelek","year":"2023","journal-title":"Radiology"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.12.003_bib0003","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.12.003_bib0004","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.eururo.2025.04.017","article-title":"Updated prostate cancer risk groups by prostate-specific membrane antigen positron emission tomography prostate cancer molecular imaging standardized evaluation (PPP2): results from an international Multicentre Registry study","volume":"88","author":"Karpinski","year":"2025","journal-title":"Eur Urol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.12.003_bib0005","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/ijc.34295","article-title":"Adherence to a risk-adapted screening strategy for prostate cancer: first results of the PROBASE trial","volume":"152","author":"Krilaviciute","year":"2023","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.12.003_bib0006","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric Magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study","volume":"80","author":"Emmett","year":"2021","journal-title":"Eur Urol"},{"issue":"11","key":"10.1053\/j.semnuclmed.2025.12.003_bib0007","first-page":"1644","article-title":"The PRIMARY score: using intraprostatic (68)Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis","volume":"63","author":"Emmett","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.12.003_bib0008","article-title":"Association between the PRIMARY score at staging prostate-specific membrane antigen positron emission tomography and overall survival among patients with newly diagnosed prostate cancer: findings from the international, Multicenter PROMISE Registry","author":"Karpinski","year":"2025","journal-title":"Eur Urol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.12.003_bib0009","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.euo.2023.11.008","volume":"7","author":"Buteau","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.12.003_bib0010","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.euo.2024.01.002","article-title":"Fluorine-18-labelled prostate-specific membrane antigen positron emission tomography\/computed tomography or magnetic resonance imaging to diagnose and localise prostate cancer. A prospective single-arm paired comparison (PEDAL)","volume":"7","author":"Wong","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.12.003_bib0011","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1007\/s00330-025-11358-x","article-title":"Discordance between prostate MRI and PSMA-PET\/CT: the next big challenge for primary prostate tumor assessment?","volume":"35","author":"Woo","year":"2025","journal-title":"Eur Radiol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.12.003_bib0012","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.12.003_bib0013","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.2967\/jnumed.123.267004","article-title":"Randomized trial of prostate-specific membrane antigen PET\/CT before definitive radiotherapy for unfavorable intermediate- and high-risk prostate cancer (PSMA-dRT Trial)","volume":"65","author":"Nikitas","year":"2024","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.12.003_bib0014","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.38550","article-title":"Performance of a prostate-specific membrane antigen positron emission tomography\/computed tomography-derived risk-stratification tool for high-risk and very high-risk prostate cancer","volume":"4","author":"Xiang","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.12.003_bib0015","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.eururo.2021.06.008","article-title":"Validation of the STAR-CAP clinical prognostic system for predicting biochemical recurrence, metastasis, and cancer-specific mortality after radical prostatectomy in a European cohort","volume":"80","author":"W\u00fcrnschimmel","year":"2021","journal-title":"Eur Urol"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.12.003_bib0016","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(24)00326-7","article-title":"Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study","volume":"25","author":"Karpinski","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2025.12.003_bib0017","article-title":"Baseline PSMA tumor volume as a prognostic marker in radical radiotherapy for prostate cancer: a propensity score-weighted retrospective analysis","author":"Lanfranchi","year":"2025","journal-title":"Ann Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.12.003_bib0018","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.eururo.2023.06.022","article-title":"Presurgical (68)Ga-PSMA-11 positron emission tomography for biochemical recurrence risk assessment: a follow-up analysis of a multicenter prospective phase 3 imaging trial","volume":"84","author":"Dja\u00efleb","year":"2023","journal-title":"Eur Urol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.12.003_bib0019","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40644-025-00907-8","article-title":"PSMA-PET-derived distance features as biomarkers for predicting outcomes in primary prostate cancer post-radical prostatectomy","volume":"25","author":"Chen","year":"2025","journal-title":"Cancer Imaging"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.12.003_bib0020","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2023.05.038","article-title":"European Association of Urology Biochemical recurrence risk classification as a decision tool for salvage radiotherapy-A multicenter study","volume":"85","author":"Preisser","year":"2024","journal-title":"Eur Urol"},{"issue":"Suppl 3","key":"10.1053\/j.semnuclmed.2025.12.003_bib0021","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/bju.15762","article-title":"Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups","volume":"130","author":"Roberts","year":"2022","journal-title":"BJU Int"},{"issue":"21","key":"10.1053\/j.semnuclmed.2025.12.003_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215461","article-title":"A risk model for patients with PSA-only recurrence (Biochemical Recurrence) based on PSA and PSMA PET\/CT: an individual patient data meta-analysis","volume":"14","author":"von Eyben","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"13","key":"10.1053\/j.semnuclmed.2025.12.003_bib0023","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17132249","article-title":"Tumor segmentation on PSMA PET\/CT predicts survival in biochemical recurrence of prostate cancer: a retrospective study using [(68)Ga]Ga-PSMA-11 and [(18)F]-PSMA-1007","volume":"17","author":"Kudura","year":"2025","journal-title":"Cancers"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.12.003_bib0024","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s12094-024-03625-y","article-title":"PSMA PET\/CT SUVmax as a prognostic biomarker in patients with metachronous metastatic hormone-sensitive prostate cancer (mHSPC)","volume":"27","author":"Henr\u00edquez","year":"2025","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.12.003_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102406","article-title":"The prognostic role of (68)GA-PSMA-PET\/CT in metastatic hormone-sensitive prostate cancer: a preliminary analysis","volume":"23","author":"Marchetti","year":"2025","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"10.1053\/j.semnuclmed.2025.12.003_bib0026","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.12.003_bib0027","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2967\/jnumed.124.268441","article-title":"Low- and high-volume disease in metastatic hormone-sensitive prostate cancer: from CHAARTED to PSMA PET-an international multicenter retrospective study","volume":"66","author":"Unterrainer","year":"2025","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.12.003_bib0028","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1007\/s00259-025-07300-4","article-title":"A visual whole-body tumor-burden classification based on PSMA PET\/CT to predict response to novel androgen receptor signaling inhibitors for metastatic hormone-sensitive prostate cancer patients","volume":"52","author":"Liao","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.12.003_bib0029","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.12.003_bib0030","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","article-title":"PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [(177)Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis","volume":"48","author":"Seifert","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.12.003_bib0031","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13122938","article-title":"PSMA expression predicts early biochemical response in patients with metastatic castration-resistant prostate cancer under (177)Lu-PSMA-617 Radioligand therapy","volume":"13","author":"Widjaja","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.12.003_bib0032","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.233460","article-title":"Quantitative (68)Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following (177)Lu-PSMA-617 (VISION Trial)","volume":"312","author":"Kuo","year":"2024","journal-title":"Radiology"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.12.003_bib0033","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1007\/s00259-025-07198-y","article-title":"Prognostic value of [(18)F]FDG- and PSMA-PET in patients evaluated for [(177)Lu]Lu-PSMA therapy of mCRPC","volume":"52","author":"Telli","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.12.003_bib0034","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after (177)Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.12.003_bib0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.euo.2024.03.009","volume":"8","author":"Gafita","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.12.003_bib0036","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s12149-021-01610-x","article-title":"Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer?","volume":"35","author":"Has Simsek","year":"2021","journal-title":"Ann Nucl Med"},{"issue":"11","key":"10.1053\/j.semnuclmed.2025.12.003_bib0037","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.2967\/jnumed.125.269584","article-title":"[(68)Ga]Ga-PSMA-11 PET tumor volume predicts overall survival of patients with metastatic prostate cancer undergoing taxane-based chemotherapy","volume":"66","author":"Beintner-Skawran","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.12.003_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2024.111774","article-title":"PSMA PET\/CT for treatment response evaluation at predefined time points is superior to PSA response for predicting survival in metastatic castration-resistant prostate cancer patients","volume":"181","author":"Kleiburg","year":"2024","journal-title":"Eur J Radiol"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.12.003_bib0039","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/S1470-2045(25)00339-0","article-title":"Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Emmett","year":"2025","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.12.003_bib0040","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1053\/j.semnuclmed.2020.08.003","article-title":"Artificial intelligence and machine learning in Nuclear medicine: future perspectives","volume":"51","author":"Seifert","year":"2021","journal-title":"Semin Nucl Med"},{"issue":"11","key":"10.1053\/j.semnuclmed.2025.12.003_bib0041","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1007\/s12149-025-02086-9","article-title":"Comparison of diagnostic performance between manual diagnosis following PROMISE V2 and aPROMISE utilizing Ga\/F-PSMA PET\/CT","volume":"39","author":"Enei","year":"2025","journal-title":"Ann Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.12.003_bib0042","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2967\/jnumed.120.261863","article-title":"aPROMISE: a novel automated PROMISE platform to standardize evaluation of tumor burden in (18)F-DCFPyL images of veterans with prostate cancer","volume":"63","author":"Nickols","year":"2022","journal-title":"J Nucl Med"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825001813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825001813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:48:43Z","timestamp":1773845323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299825001813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0001299825001813"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.12.003","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The value of PSMA PET for risk stratification in prostate cancer: an update and future aspects","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}